News coverage about Endologix (NASDAQ:ELGX) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Endologix earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 46.9778739381029 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Endologix CEO Out (ocbj.com)
- Endologix (ELGX) Given a $5.00 Price Target by Oppenheimer Analysts (americanbankingnews.com)
- John McDermott Steps Down as Endologix (ELGX) CEO (streetinsider.com)
- Endologix reports 4Q loss (finance.yahoo.com)
- Endologix (ELGX) Issues Earnings Results (americanbankingnews.com)
Shares of Endologix (NASDAQ ELGX) opened at $4.30 on Tuesday. The company has a current ratio of 2.90, a quick ratio of 2.11 and a debt-to-equity ratio of 2.61. Endologix has a fifty-two week low of $3.75 and a fifty-two week high of $7.66. The stock has a market capitalization of $339.17, a PE ratio of -5.37 and a beta of 0.42.
Several research firms have commented on ELGX. ValuEngine cut Endologix from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. JPMorgan Chase & Co. cut Endologix from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Royal Bank of Canada decreased their target price on Endologix from $5.00 to $4.00 and set a “sector perform” rating for the company in a report on Wednesday, November 8th. Piper Jaffray Companies reiterated an “overweight” rating on shares of Endologix in a report on Tuesday, December 12th. Finally, Zacks Investment Research cut Endologix from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $5.41.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.